

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|              |   |              |           |
|--------------|---|--------------|-----------|
| Applicant :  | Gantier <i>et al.</i>                                     | Art Unit :   | 1647      |
| Serial No. : | 10/658,834  | Patent No. : | 7,611,700 |
| Filed :      | September 8, 2003   | Conf. No. :  | 7681      |
| Cust. No. :  | 13565   |              |           |
| Title :      | PROTEASE RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDES |              |           |

**POWER OF ATTORNEY BY ASSIGNEE**

Dear Sir:

As the below-named assignee of the above-identified application ("Application"), HANALL BIOPHARMA CO., LTD., through its duly-delegated representative, hereby appoints the following as its attorneys, with full power of substitution and revocation, to prosecute the Application and to transact all business in the United States Patent and Trademark Office connected therewith:

STEPHANIE SEIDMAN, Registration No. 33,779  
FRANK J. MISKIEL, Registration No. 53,332  
KAREN G. POTTER, Registration No. 57,254; and  
The ATTORNEYS of U.S. CUSTOMER NO. 13565.

**STATEMENT UNDER 37 C.F.R. 3.73(b):**

HANALL BIOPHARMA CO., LTD. is the assignee of the entire right, title and interest in the above-identified application by virtue of a chain of title from the inventors of the application listed above and its priority applications/patents, to the current assignee as follows:

Assignment from Rene Gantier; Manuel Vega; Lila Drittanti; and Thierry Guyon to Nautilus Biotech, S.A., recorded in the United States Patent and Trademark Office on Reel 014957, Frame 0642; License Agreement from Nautilus Biotech, S.A. to Creabilis Therapeutics SPA, recorded in the United States Patent and Trademark Office on Reel 021521, Frame 0699; Assignment from Nautilus Biotech, S.A. to HANALL PHARMACEUTICAL CO., LTD., recorded in the United States Patent and Trademark Office on Reel 023006, Frame 0088; corrective Assignment from Nautilus Biotech S.A. to HANALL PHARMACEUTICAL CO., LTD., recorded in the United States Patent and Trademark Office on Reel 023294, Frame 0328; name change from HANALL PHARMACEUTICAL CO., LTD. to HANALL BIOPHARMA

Applicant: : Gantier *et al.*  
Serial No. : 10/658,834  
Filed : September 8, 2003

Attorney Docket No.: 33332.00922.US02/922  
Power of Attorney

CO., LTD., recorded in the United States Patent and Trademark Office on Reel 024380, Frame 0192 for U.S. Serial No. 10/658,834, now issued as U.S. Patent No. 7,611,700, the present patent.

Direct all Correspondence to: **USPTO CUSTOMER NO. 13565**


McKENNA LONG & ALDRIDGE, LLP  
4435 Eastgate Mall, Suite 400  
San Diego, California 92121

Direct all telephonic inquiries to:

Stephanie Seidman, Registration No. 33,779  
Telephone: 619-595-8010

The undersigned is authorized to act on behalf of the assignee:

**HANALL BIOPHARMA CO., LTD.**

By:   
(Signature)

Name: SEUNG HO LEE  
(Typed or Printed Name)

Title: Deputy General Manager

Date: July 7, 2011